% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Summer, I think the results for IPI-504 may be the worst clinical trial results I've ever seen, certainly for a drug that got as far as phase 2. Virtually no improvement in PSA or tumor burden, the chosen endpoints, and "unacceptable levels of toxicity" including a couple of deaths (in a small population) that appeared to be drug-related.

      Fortunately, OGX-427 is targeting a different heat shock protein in a different way, and if the phase 1 results mean anything the phase 2 results will at least be better than those for Infinity's drug.

      I share the hope you expressed in a different post that OGXI will finally provide some timeline guidance on its trials tomorrow. OGXI has had quite a news drought of late. I don't think we've heard from Cormack since the Q1 conference call. I can barely remember what he sounds like.

      A minor observation: I notice that they no longer seem to be listing SN-2310 as a product candidate. I guess they've given up on trying to outlicense it.

0.558-0.017(-2.96%)3:06 PMEDT